Potential relationship between the selenoproteome and cancer

Jia,Yi; Dai,Jie; Zeng,Zhu

doi:10.3892/mco.2020.2153

Potential relationship between the selenoproteome and cancer

Authors:
- Yi Jia
- Jie Dai
- Zhu Zeng
View Affiliations

Affiliations: Immune Cells and Antibody Engineering Research Center of Guizhou Province/Key Laboratory of Biology and Medical Engineering, Guizhou Medical University, Guiyang, Guizhou 550025, P.R. China, School of Biology and Engineering, Guizhou Medical University, Guiyang, Guizhou 550025, P.R. China
Published online on: October 11, 2020 https://doi.org/10.3892/mco.2020.2153
Article Number: 83
Copyright: © Jia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of the selenoproteome, which is the collection of all proteins containing selenium in an organism, in cancer development, growth and progression requires further investigation, due to the importance of selenium in both cancer and immune system function. Data about the selenoproteome, including its differential expression, single nucleotide variations, copy number variations, methylation, pathways and overall survival (OS) in five leading types of cancer are available from the GSCALite website. Subsequent to the analysis of these datasets, it was revealed that there was increased expression of GPX3 in stomach adenocarcinoma and lung squamous cell carcinoma, SELENOV in oesophageal carcinoma, GPX8 and GPX4 in colon adenocarcinoma, TXNRD1 and SEPHS1 in hepatocellular carcinoma and GPX8 in lung adenocarcinoma were associated with poor survival. Decreased gene expression of SELENOP was indicated in liver hepatocellular carcinoma and GPX3, and SELENOW, SELENOK, SELENBP1 and SECISBP2 in lung adenocarcinoma were associated with a poor prognosis. OS data suggested that hypermethylation of GPX4 in colon adenocarcinoma, GPX8 in lung squamous cell carcinoma, GPX1 in stomach adenocarcinoma and GPX3 in lung adenocarcinoma was associated with low survival, as is hypomethylation of GPX5 in lung adenocarcinoma. The selenoproteome is heterogeneous, especially in its effect on the OS of patients with cancer. The present study demonstrated that the roles of GPX4 in colon adenocarcinoma, SCLY and SELENOV in oesophageal carcinoma, SEPHS1 in liver hepatocellular carcinoma, SELENOK in lung cancer, as well as SELENOM and SELENOW in stomach adenocarcinoma requires further research. The present study may lead to the identification of novel biomarkers or potential therapeutic targets for use in the treatment of cancers, such as colon adenocarcinoma, oesophageal carcinoma, liver hepatocellular carcinoma, lung cancer and stomach adenocarcinoma.

View Figures

View References

1	Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 144:1941–1953. 2019.PubMed/NCBI View Article : Google Scholar
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
3	Feng RM, Zong YN, Cao SM and Xu RH: Current cancer situation in China: Good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond). 39(22)2019.PubMed/NCBI View Article : Google Scholar
4	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016.PubMed/NCBI View Article : Google Scholar
5	Chen W, Zheng R, Zhang S, Zeng H, Xia C, Zuo T, Yang Z, Zou X and He J: Cancer incidence and mortality in China, 2013. Cancer Lett. 401:63–71. 2017.PubMed/NCBI View Article : Google Scholar
6	Gatzka MV: Targeted tumor therapy remixed-an update on the use of small-molecule drugs in combination therapies. Cancers (Basel). 10(155)2018.PubMed/NCBI View Article : Google Scholar
7	Avery JC and Hoffmann PR: Selenium, selenoproteins, and immunity. Nutrients. 10(1203)2018.PubMed/NCBI View Article : Google Scholar
8	Huang Z, Rose AH and Hoffmann PR: The role of selenium in inflammation and immunity: From molecular mechanisms to therapeutic opportunities. Antioxid Redox Sign. 16:705–743. 2012.PubMed/NCBI View Article : Google Scholar
9	Fairweather-Tait SJ, Bao Y, Broadley MR, Collings R, Ford D, Hesketh JE and Hurst R: Selenium in human health and disease. Antioxid Redox Sign. 14:1337–1383. 2011.PubMed/NCBI View Article : Google Scholar
10	Rayman MP: Selenium and human health. Lancet. 379:1256–1268. 2012.PubMed/NCBI View Article : Google Scholar
11	Short SP and Williams CS: Selenoproteins in tumorigenesis and cancer progression. Adv Cancer Res. 136:49–83. 2017.PubMed/NCBI View Article : Google Scholar
12	Méplan C: Association of single nucleotide polymorphisms in selenoprotein genes with cancer risk. Methods Mol Biol. 1661:313–324. 2018.PubMed/NCBI View Article : Google Scholar
13	Hatfield DL, Carlson BA, Tsuji PA, Tobe R and Gladyshev VN: Selenium and cancer. In: Molecular, Genetic, and Nutritional Aspects of Major and Trace Minerals. Collins J (ed). Academic Press, New York, NY, pp463-473, 2017.
14	Meyer HA, Endermann T, Stephan C, Stoedter M, Behrends T, Wolff I, Jung K and Schomburg L: Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients. PLoS One. 7(e46644)2012.PubMed/NCBI View Article : Google Scholar
15	Lincoln DT, Ali EME, Tonissen KF and Clarke FM: The thioredoxin-thioredoxin reductase system: Over-expression in human cancer. Anticancer Res. 23:2425–2433. 2003.PubMed/NCBI
16	Jabłońska E and Reszka E: Selenium and epigenetics in cancer: Focus on DNA methylation. Adv Cancer Res. 136:193–234. 2017.PubMed/NCBI View Article : Google Scholar
17	Liu CJ, Hu FF, Xia MX, Han L, Zhang Q and Guo AY: GSCALite: A web server for gene set cancer analysis. Bioinformatics. 34:3771–3772. 2018.PubMed/NCBI View Article : Google Scholar
18	Győrffy B, Surowiak P, Budczies J and Lánczky A: Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 8(e82241)2013.PubMed/NCBI View Article : Google Scholar
19	Menyhárt O, Nagy Á and Győrffy B: Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 5(181006)2018.PubMed/NCBI View Article : Google Scholar
20	Yagublu V, Arthur JR, Babayeva SN, Nicol F, Post S and Keese M: Expression of selenium-containing proteins in human colon carcinoma tissue. Anticancer Res. 31:2693–2698. 2011.PubMed/NCBI
21	Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J and Powis G: Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res. 16:3459–3466. 1996.PubMed/NCBI
22	Murawaki Y, Tsuchiya H, Kanbe T, Harada K, Yashima K, Nozaka K, Tanida O, Kohno M, Mukoyama T, Nishimuki E, et al: Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett. 259:218–230. 2008.PubMed/NCBI View Article : Google Scholar
23	Peters KM, Carlson BA, Gladyshev VN and Tsuji PA: Selenoproteins in colon cancer. Free Radic Biol Med. 127:14–25. 2018.PubMed/NCBI View Article : Google Scholar
24	Méplan C and Hesketh J: The influence of selenium and selenoprotein gene variants on colorectal cancer risk. Mutagenesis. 27:177–186. 2012.PubMed/NCBI View Article : Google Scholar
25	Méplan C, Hughes DJ, Pardini B, Naccarati A, Soucek P, Vodickova L, Hlavatá I, Vrána D, Vodicka P and Hesketh JE: Genetic variants in selenoprotein genes increase risk of colorectal cancer. Carcinogenesis. 31:1074–1079. 2010.PubMed/NCBI View Article : Google Scholar
26	Wang W, Green M, Choi JE, Gijón M, Kennedy PD, Johnson JK, Liao P, Lang X, Kryczek I, Sell A, et al: CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 569:270–274. 2019.PubMed/NCBI View Article : Google Scholar
27	Hassannia B, Vandenabeele P and Berghe TV: Targeting ferroptosis to iron out cancer. Cancer Cell. 35:830–849. 2019.PubMed/NCBI View Article : Google Scholar
28	Lei Z, Tian D, Zhang C, Zhao S and Su M: Clinicopathological and prognostic significance of GPX2 protein expression in esophageal squamous cell carcinoma. BMC Cancer. 16(410)2016.PubMed/NCBI View Article : Google Scholar
29	Silvers AL, Lin L, Bass AJ, Chen G, Wang Z, Thomas DG, Lin J, Giordano TJ, Orringer MB, Beer DG and Chang AC: Decreased selenium-binding protein 1 in esophageal adenocarcinoma results from posttranscriptional and epigenetic regulation and affects chemosensitivity. Clin Cancer Res. 16:2009–2021. 2010.PubMed/NCBI View Article : Google Scholar
30	Takata Y, Kristal AR, Santella RM, King IB, Duggan DJ, Lampe JW, Rayman MP, Blount PL, Reid BJ, Vaughan TL and Peters U: Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: Results from biomarkers and genetic variants. PLoS One. 7(e38612)2012.PubMed/NCBI View Article : Google Scholar
31	Steevens J, Schouten LJ, Driessen ALC, Huysentruyt CJ, Keulemans YC, Goldbohm RA and van den Brandt PA: Toenail selenium status and the risk of Barrett's esophagus: The Netherlands Cohort Study. Cancer Causes Control. 21:2259–2268. 2010.PubMed/NCBI View Article : Google Scholar
32	Seale LA: Selenocysteine β-Lyase: Biochemistry, regulation and physiological role of the selenocysteine decomposition enzyme. Antioxidants (Basel). 8(357)2019.PubMed/NCBI View Article : Google Scholar
33	Li CL, Nan KJ, Tian T, Sui CG and Liu YF: Selenoprotein P mRNA expression in human hepatic tissues. World J Gastroenterol. 13:2363–2368. 2007.PubMed/NCBI View Article : Google Scholar
34	Zheng Y, Liu Y, Zhao S, Zheng Z, Shen C, An L and Yuan Y: Large-scale analysis reveals a novel risk score to predict overall survival in hepatocellular carcinoma. Cancer Manag Res. 10:6079–6096. 2018.PubMed/NCBI View Article : Google Scholar
35	Lee D, Xu IMJ, Chiu DKC, Leibold J, Tse AP, Bao MH, Yuen VW, Chan CY, Lai RK, Chin DW, et al: Induction of oxidative stress through inhibition of thioredoxin reductase 1 is an effective therapeutic approach for hepatocellular carcinoma. Hepatology. 69:1768–1786. 2019.PubMed/NCBI View Article : Google Scholar
36	Tuo L, Xiang J, Pan X, Gao Q, Zhang G, Yang Y, Liang L, Xia J, Wang K and Tang N: PCK1 downregulation promotes TXNRD1 expression and hepatoma cell growth via the Nrf2/Keap1 pathway. Front Oncol. 8(611)2018.PubMed/NCBI View Article : Google Scholar
37	Gao Q, Zhang G, Zheng Y, Yang Y, Chen C, Xia J, Liang L, Lei C, Hu Y, Cai X, et al: SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC. Cell Death Differ. 27:1086–1104. 2020.PubMed/NCBI
38	Fu B, Meng W, Zeng X, Zhao H, Liu W and Zhang T: TXNRD1 is an unfavorable prognostic factor for patients with hepatocellular carcinoma. Biomed Res Int. 2017(4698167)2017.PubMed/NCBI View Article : Google Scholar
39	Shang N, Wang X, Shu Q, Wang H and Zhao L: The functions of selenium and selenoproteins relating to the liver diseases. J Nanosci Nanotechnol. 19:1875–1888. 2019.PubMed/NCBI View Article : Google Scholar
40	Tarek M, Louka ML, Khairy E, Ali-Labib R, Zakaria Zaky D and Montasser IF: Role of microRNA-7 and selenoprotein P in hepatocellular carcinoma. Tumor Biol. 39(1010428317698372)2017.PubMed/NCBI View Article : Google Scholar
41	Hughes DJ, Duarte-Salles T, Hybsier S, Trichopoulou A, Stepien M, Aleksandrova K, Overvad K, Tjønneland A, Olsen A, Affret A, et al: Prediagnostic selenium status and hepatobiliary cancer risk in the European Prospective Investigation into Cancer and Nutrition cohort. Am J Clin Nutr. 104:406–414. 2016.PubMed/NCBI View Article : Google Scholar
42	DI Stasio M, Volpe MG, Colonna G, Nazzaro M, Polimeno M, Scala S, Castello G and Costantini S: A possible predictive marker of progression for hepatocellular carcinoma. Oncol Lett. 2:1247–1251. 2011.PubMed/NCBI View Article : Google Scholar
43	Jia Y, Dai J, Zhang LL and Xia H: Biological functions of selenium-binding protein 1 and its relationship with diseases. Prog Biochem Biophys. 46:128–137. 2019.
44	Guariniello S, Colonna G, Raucci R, Costantini M, Di Bernardo G, Bergantino F, Castello G and Costantini S: Structure-function relationship and evolutionary history of the human selenoprotein M (SelM) found over-expressed in hepatocellular carcinoma. Biochim Biophys Acta. 1844:447–456. 2014.PubMed/NCBI View Article : Google Scholar
45	Na J, Jung J, Bang J, Lu Q, Carlson BA, Guo X, Gladyshev VN, Kim J, Hatfield DL and Lee BJ: Selenophosphate synthetase 1 and its role in redox homeostasis, defense and proliferation. Free Radic Biol Med. 127:190–197. 2018.PubMed/NCBI View Article : Google Scholar
46	Jaworska K, Gupta S, Durda K, Muszyńska M, Sukiennicki G, Jaworowska E, Grodzki T, Sulikowski M, Waloszczyk P, Wójcik J, et al: A low selenium level is associated with lung and laryngeal cancers. PLoS One. 8(e59051)2013.PubMed/NCBI View Article : Google Scholar
47	Epplein M, Burk RF, Cai Q, Hargreaves MK and Blot WJ: A prospective study of plasma Selenoprotein P and lung cancer risk among low-income adults. Cancer Epidemiol Biomarkers Prev. 23:1238–1244. 2014.PubMed/NCBI View Article : Google Scholar
48	Gresner P, Gromadzinska J, Jablonska E, Kaczmarski J and Wasowicz W: Expression of selenoprotein-coding genes SEPP1, SEP15 and hGPX1 in non-small cell lung cancer. Lung Cancer. 65:34–40. 2009.PubMed/NCBI View Article : Google Scholar
49	An BC, Choi YD, Oh IJ, Kim JH, Park JI and Lee SW: GPx3-mediated redox signaling arrests the cell cycle and acts as a tumor suppressor in lung cancer cell lines. PLoS One. 13(e0204170)2018.PubMed/NCBI View Article : Google Scholar
50	Oh IJ, Kim HE, Song SY, Na KJ, Kim KS, Kim YC and Lee SW: Diagnostic value of serum glutathione peroxidase 3 levels in patients with lung cancer. Thorac Cancer. 5:425–430. 2014.PubMed/NCBI View Article : Google Scholar
51	Choi JY, An BC, Jung IJ, Kim JH and Lee SW: MiR-921 directly downregulates GPx3 in A549 lung cancer cells. Gene. 700:163–167. 2019.PubMed/NCBI View Article : Google Scholar
52	Chen G, Wang H, Miller CT, Thomas DG, Gharib TG, Misek DE, Giordano TJ, Orringer MB, Hanash SM and Beer DG: Reduced selenium-binding protein 1 expression is associated with poor outcome in lung adenocarcinomas. J Pathol. 202:321–329. 2004.PubMed/NCBI View Article : Google Scholar
53	Marciel MP, Khadka VS, Deng Y, Kilicaslan P, Pham A, Bertino P, Lee K, Chen S, Glibetic N, Hoffmann FW, et al: Selenoprotein K deficiency inhibits melanoma by reducing calcium flux required for tumor growth and metastasis. Oncotarget. 9:13407–3422. 2018.PubMed/NCBI View Article : Google Scholar
54	Jeong D, Kim TS, Chung YW, Lee BJ and Kim IY: Selenoprotein W is a glutathione-dependent antioxidant in vivo. FEBS Lett. 517:225–228. 2002.PubMed/NCBI View Article : Google Scholar
55	Xu X, Huang L, Chan CH, Yu T, Miao R and Liu C: Assessing the clinical utility of genomic expression data across human cancers. Oncotarget. 7:45926–45936. 2016.PubMed/NCBI View Article : Google Scholar
56	Marciel MP and Hoffmann PR: Molecular mechanisms by which Selenoprotein K regulates immunity and cancer. Biol Trace Elem Res. 192:60–68. 2019.PubMed/NCBI View Article : Google Scholar
57	Min SY, Kim HS, Jung EJ, Do Jee C and Kim WH: Prognostic significance of glutathione peroxidase 1 (GPX1) down-regulation and correlation with aberrant promoter methylation in human gastric cancer. Anticancer Res. 32:3169–3175. 2012.PubMed/NCBI
58	Peng DF, Hu TL, Schneider BG, Chen Z, Xu ZK and El-Rifai W: Silencing of glutathione peroxidase 3 through DNA hypermethylation is associated with lymph node metastasis in gastric carcinomas. PLoS One. 7(e46214)2012.PubMed/NCBI View Article : Google Scholar
59	Lan X, Xing J, Gao H, Li S, Quan L, Jiang Y, Ding S and Xue Y: Decreased expression of selenoproteins as a poor prognosticator of gastric cancer in humans. Biol Trace Elem Res. 178:22–28. 2017.PubMed/NCBI View Article : Google Scholar
60	Zhang J, Dong W and Lin J: Reduced selenium-binding protein 1 is associated with poor survival rate in gastric carcinoma. Med Oncol. 28:481–487. 2011.PubMed/NCBI View Article : Google Scholar
61	Wang Q, Gong L, Dong R, Qiao Q, He XL, Chu YK, Du XL, Yang Y, Zang L, Nan J, et al: Tissue microarray assessment of selenoprotein P expression in gastric adenocarcinoma. J Int Med Res. 37:169–174. 2009.PubMed/NCBI View Article : Google Scholar